DENVER — UrgentRx on Monday named Michael Valentino to the company's board. Valentino brings more than 30 years of leadership experience at both major pharmaceutical companies and venture-backed start-ups. His most recent commercial responsibility was with Xanodyne Pharmaceuticals as president and CEO, UrgentRx reported.
“Valentino is going to make an extraordinary addition to our already very strong board,” stated Jordan Eisenberg, president of UrgentRx. “Mike’s leadership, vision and ability to succeed within the OTC and pharmaceutical world make him a great fit for UrgentRx. This is an exciting time for us and we are honored to have a person of his caliber join our team.”
“I’m impressed by the way UrgentRx is looking to disrupt the OTC category and thrilled to be a part of a company that sees beyond the status quo of the OTC aisle," Valentino said. "The company is looking at innovative ways to reach the consumer both in and outside the traditional retail space, which is very exciting."
Valentino has a strong pedigree of success in the OTC aisles behind him. Prior to joining Xanodyne, Valentino successfully built start-up Adams Respiratory Therapeutics into a specialty pharmaceutical company with nearly $500 million in annual revenue and such leading OTC brands as Mucinex and Delsym. Valentino also served in executive roles at Alpharma, a leading global generic pharmaceutical company, Novartis, Novartis Consumer Healthcare, North America and Novartis Nutrition Corporation. Valentino also was president of Pharmacia & Upjohn’s consumer products division and previously spent 12 years at Warner Lambert in a variety of senior level roles.